AMARYL 2.0 TABLETS 2 mg

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Active ingredient:

GLIMEPIRIDE

Available from:

SANOFI-AVENTIS SINGAPORE PTE. LTD.

ATC code:

A10BB12

Dosage:

2 mg

Pharmaceutical form:

TABLET

Composition:

GLIMEPIRIDE 2 mg

Administration route:

ORAL

Prescription type:

Prescription Only

Manufactured by:

SANOFI SRL

Authorization status:

ACTIVE

Authorization date:

1998-11-20

Patient Information leaflet

AMARYL 1MG 
AMARYL 2MG 
AMARYL 3MG 
_Glimepiride Tablets _

[SANOFI LOGO] 

This package insert is continually updated: please read carefully
before using a new pack. In 
case of any question, please contact your physician or pharmacist. 

COMPOSITION 
Each Amaryl tablet contains, as active ingredient, 1mg or 2 mg or
3 mg glimepiride. 

Excipients: Lactose monohydrate, sodium starch glycolate,
magnesium stearate, microcrystalline 
cellulose, polyvidone 25000, red iron oxide (Amaryl 1 mg), yellow
iron oxide (Amaryl 2 mg and 
Amaryl 3 mg), indigo carmine aluminium lake (Amaryl 2 mg). 

PHARMACEUTICAL FORM 
Tablet 

_Amaryl 1 mg tablets: _
The tablets are pink, oblong and scored on both sides. 

_Amaryl 2 mg tablets: _
The tablets are green, oblong and scored on both sides. 

_Amaryl 3 mg tablets: _
The tablets are pale yellow, oblong and scored on both sides. 

The tablet can be divided into equal doses. 

THERAPEUTIC INDICATIONS 
Non-insulin-dependent (type II) diabetes mellitus, whenever blood
sugar levels cannot be  
controlled adequately by diet, physical exercise and weight reduction
alone. Amaryl may also 
be used in combination with an oral antidiabetic containing
metformin or with insulin. 

POSOLOGY AND METHOD OF ADMINISTRATION  
For oral administration 
The basis for successful treatment of diabetes is a good diet, regular
physical activity, as well as routine 
checks of blood and urine. Tablets or insulin cannot compensate if
the patient does not keep to the 
recommended diet. 

Posology 
Dose is determined by the results of blood and urinary glucose
determinations. 
The starting dose is 1 mg glimepiride per day. If good control is
achieved this dose should be used for 
maintenance therapy. 
For the different dose regimens appropriate strengths
are available. 
If control is unsatisfactory the dose should be increased, based on
the glycaemic control, in a stepwise 
manner with an interval of about 1 to

Summary of Product characteristics

AMARYL 1MG
AMARYL 2MG
AMARYL 3MG
_Glimepiride Tablets _
[SANOFI LOGO]
This package insert is continually updated: please read carefully
before using a new pack. In
case of any question, please contact your physician or pharmacist.
COMPOSITION
Each Amaryl tablet contains, as active ingredient, 1mg or 2 mg or 3 mg
glimepiride.
Excipients: Lactose monohydrate, sodium starch glycolate, magnesium
stearate, microcrystalline
cellulose, polyvidone 25000, red iron oxide (Amaryl 1 mg), yellow iron
oxide (Amaryl 2 mg and
Amaryl 3 mg), indigo carmine aluminium lake (Amaryl 2 mg).
PHARMACEUTICAL FORM
Tablet
_Amaryl 1 mg tablets: _
The tablets are pink, oblong and scored on both sides.
_Amaryl 2 mg tablets: _
The tablets are green, oblong and scored on both sides.
_Amaryl 3 mg tablets: _
The tablets are pale yellow, oblong and scored on both sides.
The tablet can be divided into equal doses.
THERAPEUTIC INDICATIONS
Non-insulin-dependent
(type
II)
diabetes
mellitus,
whenever
blood
sugar
levels
cannot
be
controlled adequately by diet, physical exercise and weight reduction
alone. Amaryl may also be
used in combination with an oral antidiabetic containing metformin or
with insulin.
POSOLOGY AND METHOD OF ADMINISTRATION
For oral administration
The basis for successful treatment of diabetes is a good diet, regular
physical activity, as well as
routine checks of blood and urine. Tablets or insulin cannot
compensate if the patient does not
keep to the recommended diet.
Posology
Dose is determined by the results of blood and urinary glucose
determinations.
The starting dose is 1 mg glimepiride per day. If good control is
achieved this dose should be
used for maintenance therapy.
For the different dose regimens appropriate strengths are available.
If control is unsatisfactory the dose should be increased, based on
the glycaemic control, in a
stepwise manner with an interval of about 1 to 2 weeks between each
step, to 2, 3 or 4 mg
glimepiride per day.
A dose of more than 4 mg glimepiride per day gives better results only
in exceptional